Sphingomyelinase, an enzyme implicated in atherogenesis, is present in atherosclerotic lesions and binds to specific components of the subendothelial extracellular matrix - PubMed (original) (raw)
Sphingomyelinase, an enzyme implicated in atherogenesis, is present in atherosclerotic lesions and binds to specific components of the subendothelial extracellular matrix
S Marathe et al. Arterioscler Thromb Vasc Biol. 1999 Nov.
Abstract
Atherosclerotic lesions contain an extracellular sphingomyelinase (SMase) activity that hydrolyzes the sphingomyelin of subendothelial low density lipoprotein (LDL). This SMase activity may promote atherosclerosis by enhancing subendothelial LDL retention and aggregation, foam cell formation, and possibly other atherogenic processes. The results of recent cell-culture studies have led to the hypothesis that a specific molecule called secretory SMase (S-SMase) is responsible for the SMase activity known to be in lesions, although its presence in atheromata had not been examined directly. Herein we provide immunohistochemical and biochemical support for this hypothesis. First, 2 different antibodies against S-SMase detected extracellular immunoreactive protein in the intima of mouse, rabbit, and human atherosclerotic lesions. Much of this material in lesions appeared in association with the subendothelial matrix. Second, binding studies in vitro demonstrated that (125)I-S-SMase adheres to the extracellular matrix of cultured aortic smooth muscle and endothelial cells, specifically to the laminin and collagen components. Third, in its bound state, S-SMase retains substantial enzymatic activity against lipoprotein substrates. Overall, these data support the hypothesis that S-SMase is an extracellular arterial wall SMase that contributes to the hydrolysis of the sphingomyelin of subendothelial LDL. S-SMase may therefore be an important participant in atherogenesis through local enzymatic effects that stimulate subendothelial retention and aggregation of atherogenic lipoproteins.
Similar articles
- Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development.
Schissel SL, Jiang X, Tweedie-Hardman J, Jeong T, Camejo EH, Najib J, Rapp JH, Williams KJ, Tabas I. Schissel SL, et al. J Biol Chem. 1998 Jan 30;273(5):2738-46. doi: 10.1074/jbc.273.5.2738. J Biol Chem. 1998. PMID: 9446580 - Secretory sphingomyelinase.
Tabas I. Tabas I. Chem Phys Lipids. 1999 Nov;102(1-2):123-30. doi: 10.1016/s0009-3084(99)00080-8. Chem Phys Lipids. 1999. PMID: 11001566 Review. - Sphingomyelinase activity of LDL: a link between atherosclerosis, ceramide, and apoptosis?
Kinnunen PK, Holopainen JM. Kinnunen PK, et al. Trends Cardiovasc Med. 2002 Jan;12(1):37-42. doi: 10.1016/s1050-1738(01)00143-8. Trends Cardiovasc Med. 2002. PMID: 11796243 Review.
Cited by
- Longitudinal Lipidomic Signature of Coronary Heart Disease in American Indian People.
Miao G, Pechlaner R, Fiehn O, Malloy KM, Zhang Y, Umans JG, Mayr M, Willeit J, Kiechl S, Zhao J. Miao G, et al. J Am Heart Assoc. 2024 Feb 6;13(3):e031825. doi: 10.1161/JAHA.123.031825. Epub 2024 Jan 31. J Am Heart Assoc. 2024. PMID: 38293910 Free PMC article. - Functional roles of sphingolipids in immunity and their implication in disease.
Lee M, Lee SY, Bae YS. Lee M, et al. Exp Mol Med. 2023 Jun;55(6):1110-1130. doi: 10.1038/s12276-023-01018-9. Epub 2023 Jun 1. Exp Mol Med. 2023. PMID: 37258585 Free PMC article. Review. - Effect of Sphingomyelinase-Treated LDLs on HUVECs.
Giuliani A, Morresi C, Mazzuferi G, Bellachioma L, Ramini D, Sabbatinelli J, Olivieri F, Bacchetti T, Ferretti G. Giuliani A, et al. Molecules. 2023 Feb 23;28(5):2100. doi: 10.3390/molecules28052100. Molecules. 2023. PMID: 36903354 Free PMC article. - The Role of Fine Particles (PM 2.5) in the Genesis of Atherosclerosis and Myocardial Damage: Emphasis on Clinical and Epidemiological Data, and Pathophysiological Mechanisms.
Chaulin AM, Sergeev AK. Chaulin AM, et al. Cardiol Res. 2022 Oct;13(5):268-282. doi: 10.14740/cr1366. Epub 2022 Oct 25. Cardiol Res. 2022. PMID: 36405225 Free PMC article. Review. - Sphingolipid metabolism and signaling in cardiovascular diseases.
Borodzicz-Jażdżyk S, Jażdżyk P, Łysik W, Cudnoch-Jȩdrzejewska A, Czarzasta K. Borodzicz-Jażdżyk S, et al. Front Cardiovasc Med. 2022 Aug 31;9:915961. doi: 10.3389/fcvm.2022.915961. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36119733 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources